Led by the chairman and CEO Jeff Aronin, Paragon Biosciences is a leading biotechnology company and incubator that improves lives through biomedical innovation. The renowned company identifies patients’ diseases and offers treatment whose availability is considered scarc (Bloomberg). Their scientific data and experience in the field of medicine drive their rational drug development strategy. It takes years to develop and create a new treatment in the industry. Currently, more than 6,000 diseases have proven it challenging to find the cure. But the company’s goal is to make those numbers smaller and bring relief to the suffering patients.
Paragon Biosciences has built and developed an array of companies that address specific clinical fields. One of them is Castle Creek Pharmaceuticals (CCP), focusing on the development of innovative therapies for patients with debilitating dermatological and rare conditions. On the other hand, the biopharmaceutical company, Harmony Biosciences, focuses on the identification, development, and commercialization of high-potential approved drugs for sleep and central nervous system disorder (CNS) patients. The Decade and Precision BP companies under the Paragon umbrella research and develop therapeutics for Alzheimer’s disease and complex treatments for rare genetic oncology diseases respectively.
Over the past decade, Jeff Aronin and his team have had 13 of their new drugs approved by the FDA. That is a trend-setting pace compared to other players in the US healthcare sector. With almost 20 years of experience in innovative healthcare and global biotech development, Jeff Aronin is a professional in drug development, rare diseases, and complex sciences. Jeff has since topped the list of most successful and innovative leaders in the field.
Jeff Aronin has chaired several biotech and pharmacy companies, among them MedCare Technologies. In the year 2000, Jeff Aronin founded Ovation Pharmaceuticals, a biopharmaceutical company in which he was the CEO and President. Jeff served the same post during the company’s acquisition and integration by Lundbeck, Inc. Jeff Aronin is also the non-executive chairman of Harmony Biosciences and Castle Creek Pharmaceuticals and co-founder to the later.
Aronin’s works and contribution to the betterment of the health industry has not gone unnoticed as over his career he has received over eight awards since 2006. Featured awards include the 2017 Weizmann Leadership Award, The 2013 Frederic A. Gibbs Discovery Award and Buyouts magazine “Deal of the Year” 2010. Jeff has an unending passion for bringing an esteemed team of researchers, scientists, and business executives together to research drug treatments and therapies.